| DC65262 |
OBX1-012
Featured
|
|
|
| DC60462 |
MIC1
Featured
|
MIC1 is a set of multi-charged lipids with four tertiary amino nitrogen atoms (4N4T) which could be constructed and applied to form novel lipid nanoparticles. 4N4T-LNPs based on MIC1 exhibit much higher mRNA translation efficiency than the approved SM-102-LNPs. 4N4T-LNPs are successfully applied to DS mRNA vaccine and the vaccines worked well against SARS-CoV-2 and its variants, including Delta and Omicron. |
|
| DC60463 |
MIC2
Featured
|
MIC2 is a set of multi-charged lipids with four tertiary amino nitrogen atoms (4N4T) which could be constructed and applied to form novel lipid nanoparticles. 4N4T-LNPs based on MIC2 exhibit much higher mRNA translation efficiency than the approved SM-102-LNPs. 4N4T-LNPs are successfully applied to DS mRNA vaccine and the vaccines worked well against SARS-CoV-2 and its variants, including Delta and Omicron. |
|
| DC65263 |
NFAT:AP-1 inhibitor-10(Compound10)
Featured
|
NFAT:AP-1 inhibitor-10 is a novel inhibitor of the NFAT:AP-1:DNA interaction on the ARRE-2 element, binding to DNA in a sequence-selective manner and inhibiting the transcription of the Il2 gene and several other cyclosporin A-sensitive cytokine genes important for the effector immune response. |
|
| DC65264 |
COMPOUND A
Featured
|
|
|
| DC65265 |
GNE-8505
Featured
|
GNE-8505 is a DLK inhibitor (IC50 = 10nM). |
|
| DC65267 |
CDK2-IN-3 (compound 3)
Featured
|
CDK2-IN-3 (compound 3) is a potent and selective CDK2 inhibitor with an 50 of 60 nM. |
|
| DC65268 |
VU0652835
Featured
|
VU0652835 is a metabotropic glutamate receptor subtype 5 (mGlu5) negative allosteric modulator with an IC50 of 81 nM. |
|
| DC65269 |
PF-4211
Featured
|
PF-4211 is a potent D1 receptor agonist. |
|
| DC65270 |
DKR-1677
Featured
|
|
|
| DC65271 |
Pseudouridimycin(PUM)
Featured
|
Pseudouridimycin (PUM), an antibiotic, is a selective bacterial RNA polymerase (RNAP) inhibitor. Pseudouridimycin is a C-nucleoside analogue that is effective against both Gram-negative and Gram-positive bacteria. |
|
| DC65272 |
HMG499
Featured
|
HMG499 is a potent and selective HMG-CoA reductase inhibitor. |
|
| DC65273 |
Compound 16
Featured
|
|
|
| DC65274 |
SGL5213
Featured
|
SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment. |
|
| DC65275 |
PFKFB3inhibitor(Compound69)
Featured
|
|
|
| DC65276 |
(S)-DO271
Featured
|
(S)-DO271 is an inactive control for the α/β-hydrolase domain-containing protein 12 (ABHD12) inhibitor DO264. |
|
| DC65277 |
JNJ-64326067
Featured
|
JNJ-64326067 is a potent and selective binder to aggregated tau with a favorable pharmacokinetic profile and no apparent off-target binding. This was confirmed in rat and monkey positron emission tomography studies using [18F]-JNJ-64326067. |
|
| DC65278 |
ABBV-4083(Compound5d)
Featured
|
ABBV-4083 is an analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity. |
|
| DC65279 |
NPD2381
Featured
|
|
|
| DC65280 |
DS21360717
Featured
|
DS21360717 is a potent and orally active FER tyrosine kinase inhibitor, with an IC50 of 0.49 nM. Anti-cancer activity. |
|
| DC65281 |
DS39201083
Featured
|
DS39201083 is a potent novel analgesic without mu opioid agonist activity. DS39201083 had a unique bicyclic skeleton and was a more potent analgesic than conolidine, as revealed in the acetic acid-induced writhing test and formalin test in ddY mice. The compound showed no agonist activity at the mu opioid receptor. |
|
| DC65282 |
NV-5440
Featured
|
NV-5440 is a novel cell penetrant, potent and selective class I glucose transporters (GLUT1) inhibitor, selectively inhibiting mTORC1 |
|
| DC65283 |
neocarzilin A
Featured
|
|
|
| DC65284 |
NC-1
Featured
|
NC-1 is a novel highly active allosteric inhibitor of protein tyrosine phosphatase, non-receptor type 22 (PTPN22) which is a lymphoid-specific tyrosine phosphatase (LYP). |
|
| DC65285 |
BA-1049
Featured
|
|
|
| DC65286 |
SWE101
Featured
|
|
|
| DC65287 |
BMS-986260
Featured
|
BMS-986260 is a potent, selective, and orally bioavailable TGFβR1 inhibitor (IC50=1.6 nM). BMS-986260 demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models. |
|
| DC65289 |
Samidorphan
Featured
|
Samidorphan, also known as ALKS-33 and RDC-0313, is an opioid modulator with μ-antagonist properties. It is under development by Alkermes for the treatment of major depressive disorder and possibly other psychiatric conditions.
|
|
| DC65290 |
SB11285
Featured
|
|
|
| DC65291 |
Onvansertib fumarate
Featured
|
Onvansertib fumarate is a A polo-like kinase 1 inhibitor, an antineoplastic |
|
